Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 25 percent increase over losses of $(0.08) per share from the
October 20, 8:32 AM
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science
September 30, 11:19 AM
According to Benzinga Pro data, during Q2, Evoke Pharma (NASDAQ:EVOK) posted sales of $236.63 thousand. Earnings were up 16.27%, but Evoke Pharma still reported an overall loss of $2.17 million.